natgillin/translations-raw huggingface dataset:
Hvis ASAT og ALAT vender tilbage til baselineværdier, og hvis patienten ikke har nogen kliniske tegn eller symptomer på hepatitis, udslæt eller andre symptomer eller fund, der tyder på organpåvirkning, er det muligt at genintroducere nevirapin efter en individuel patientvurdering, med en startdosis én gang dagligt i 14 dage af Viramune tabletter 200 mg efterfulgt af Viramune depottabletter én gang dagligt.
If ASAT and ALAT return to baseline values and if the patient had no clinical signs or symptoms of hepatitis, rash, constitutional symptoms or other findings suggestive of organ dysfunction, it may be possible to reintroduce nevirapine, on a case by case basis, at the starting dose regimen of one immediate-release 200 mg Viramune tablet daily for 14 days followed by one Viramune 400 mg prolonged-release tablet daily.
Viramune 100 mg depottabletter nevirapin
Viramune 100 mg prolonged-release tablets nevirapine
Naturlægemidler indeholdende perikon og Viramune må ikke coadministreres (se pkt.
Herbal preparations containing St. John‘s Wort and Viramune must not be co-administered (see section 4.3).
Granulocytopeni, lægemiddelreaktion med systemiske symptomer, anafylaktisk reaktion, gulsot, fulminant hepatitis (som kan være letal), urticaria, nedsat fosfor i blodet og øget blodtryk forekom ikke under optrapningsfasen med Viramune med øjeblikkelig udløsning i studie 1100.1486.
As granulocytopenia, drug reaction with eosinophilia and systemic symptoms, anaphylactic reaction, jaundice, hepatitis fulminant (which may be fatal), urticaria, decreased blood phosphorus and increased blood pressure during the lead-in phase with Viramune immediate release were not seen in study 1100.1486 the frequency category was estimated from a statistical calculation based on the total number of patients exposed to nevirapine immediate-release in the lead-in phase of the randomised controlled clinical study 1100.1486 (n= 1,068).
Raltegravir og Viramune kan coadministreres uden dosisjustering.
Raltegravir and Viramune can be coadministered without dose adjustments.
Det anbefales, at foretage en nøje hepatisk monitorering.
Close monitoring for hepatic abnormalities is recommended
Viramune kan tages både med og uden mad.
Viramune can be taken with or without food.
Almindelig (kan forekomme hos op til 1 ud af 10 patienter): - udslæt - feber - hovedpine - mavesmerter - kvalme - diarré - træthed
Common (may affect up to 1 in 10 people): - rash - fever - headache - abdominal pain - feeling sick (nausea) - loose stools (diarrhoea) - feeling tired (fatigue)
- generel hævelse - åndenød - muskel- eller ledsmerter - generel følelse af at være syg - mavesmerter overfølsomhedsreaktioner (allergiske) leverbetændelse (hepatitis) hvis du har en alvorlig leversygdom hvis du tidligere har været nødt til at stoppe behandling med Viramune på grund af ændringer i din leverfunktion hvis du tager naturmedicin, som indeholder perikon (Hypericum perforatum).
- general swelling - shortness of breath - muscle or joint pain - general feelings of illness - abdominal pain - hypersensitivity (allergic) reactions - inflammation of the liver (hepatitis) - if you have severe liver disease - if you have had to stop Viramune treatment in the past because of changes in your liver function - if you are taking a medicine containing the herbal substance St. John's Wort (Hypericum perforatum).
Abacavir hæmmer ikke CYP-isoformer i humane levermikrosomer.
In human liver microsomes, abacavir did not inhibit cytochrome P450 isoforms.
Lamivudin og Viramune kan coadministreres uden dosisjustering.
Lamivudine and Viramune can be coadministered without dose adjustments.
Almindelig (kan forekomme hos op til 1 ud af 10 patienter): - udslæt - hovedpine - mavesmerter - kvalme - leverbetændelse (hepatitis) - træthed - leverfunktionsprøver uden for normalområdet - feber - opkastning - diarré
Common (may affect up to 1 in 10 people): - rash - headache - abdominal pain - feeling sick (nausea) - inflammation of the liver (hepatitis) - feeling tired (fatigue) - abnormal liver function tests - fever - vomiting - loose stools (diarrhoea)
Telbivudin er ikke substrat, inducer eller hæmmer af CYP-enzymsystemet.
Telbivudine is not a substrate, inducer or inhibitor of the cytochrome P450 (CYP450) enzyme system.
Atazanavir/ritonavir 300/100 mg 4 gange dagligt
Atazanavir/ritonavir 300/100 mg QD 400/100 mg QD
Hepatitis (inklusive svær og livstruende hepatotoksicitet)(0,09 %)
severe and life-threatening hepatotoxicity)(0.09%) Skin and subcutaneous tissue disorders Common rash (6.7 %)
Hos pædiatriske patienter med nedsat nyrefunktion, som er i dialysebehandling, anbefales det, at patienten efter hver dialysebehandling får en ekstra dosis Viramune oral suspension eller 200 mg tabletter svarende til 50 % af den anbefalede daglige dosis Viramune oral suspension eller 200 mg tabletter for at afhjælpe effekten af dialyse på nevirapinclearance.
In paediatric patients with renal dysfunction who are undergoing dialysis it is recommended that following each dialysis treatment patients receive an additional dose of Viramune oral suspension or immediate-release tablets representing 50 % of the recommended daily dose of Viramune oral suspension or immediate-release tablets which would help offset the effects of dialysis on nevirapine clearance.
Tipranavir og Viramune kan coadministreres uden dosisjustering.
Tipranavir and Viramune can be coadministered without dose adjustments.
Ritonavir og Viramune kan coadministreres uden dosisjustering.
Ritonavir and Viramune can be coadministered without dose adjustments.
Hvis, der er gået mere end 8 timer, skal du springe den glemte dosis over og tage næste dosis til sædvanlig tid.
If it has been more than 8 hours since the dose was due only take the next dose at the usual time.
Monitoreringsplanen påvirkes ikke af, at patienten skifter fra Viramune med umiddelbar frigivelse to gange dagligt til Viramune depottabletter én gang dagligt.
For patients already on a regimen of Viramune immediate-release twice daily who switch to Viramune prolonged-release once daily there is no need for a change in their monitoring schedule.
Ikke almindelig (kan forekomme hos op til 1 ud af 100 patienter): - allergisk reaktion karakteriseret ved udslæt, hævelse af ansigt, åndenød (sammensnøring af luftvejene) eller anafylaktisk shock - fald i antallet af røde blodlegemer (anæmi) - gulsot (huden bliver gul) - alvorlige og livstruende hudreaktioner (Stevens-Johnsons syndrom/toksisk epidermal nekrolyse) - nældefeber - væskedannelse under huden (angioødem) - ledsmerter - muskelsmerter (myalgi) - nedsat phosphat i blodet - forhøjet blodtryk
Uncommon (may affect up to 1 in 100 people): - allergic reaction characterized by rash, swelling of the face, difficulty breathing (bronchial spasm) or anaphylactic shock - decreased numbers of red blood cells (anaemia) - yellow skin (jaundice) - severe and life-threatening skin rashes (Stevens-Johnson syndrome/ toxic epidermal necrolysis) - hives (urticaria) - fluid under the skin (angioedema) - joint pain (arthralgia) - muscle pain (myalgia) - decreased blood phosphorus - increased blood pressure
LÆGEMIDLETS NAVN Viramune 400 mg depottabletter nevirapin
NAME OF THE MEDICINAL PRODUCT Viramune 400 mg prolonged-release tablets nevirapine
Blod- og lymfesystem Ikke almindelig:
Blood and lymphatic system disorders Uncommon anaemia, granulocytopenia
Det skal du vide, før du begynder at tage Viramune Sådan skal du tage Viramune Bivirkninger
What Viramune is and what it is used for What you need to know before you take Viramune How to take Viramune
Pædiatriske patienter med nedsat nyrefunktion, som har behov for dialyse, bør efter hver dialysebehandling have en ekstra dosis Viramune oral suspension eller almindelig tabletter svarende til 50 % af den anbefalede daglige dosis Viramune oral suspension eller tabletter for at afhjælpe effekten af dialyse på nevirapin-clearance.
In paediatric patients with renal dysfunction who are undergoing dialysis it is recommended following each dialysis treatment patients receive an additional dose of Viramune oral suspension or immediate-release tablets representing 50% of the recommended daily dose of Viramune oral suspension or immediate-release tablets, which would help offset the effects of dialysis on nevirapine clearance.
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER 1 depottablet indeholder 400 mg nevirapin (vandfri).
STATEMENT OF ACTIVE SUBSTANCE(S) Each prolonged-release tablet contains 400 mg of nevirapine (as anhydrous)
Viramune depottabletter indeholder lactose.
Viramune prolonged-release tablets contain lactose (milk sugar).
Viramune og emtricitabin kan coadministreres uden dosisjustering.
Viramune and emtricitabine may be coadministered without dose adjustments.
Hvis, der er gået mere end 12 timer, skal du springe den glemte dosis over og tage næste dosis til sædvanlig tid.
If it has been more than 12 hours since the dose was due only take the next dose at the usual time.
Tabel 4: Lipidværdier ved baseline (screening) og efter uge 48 - studie 1100.1486 Viramune 200 mg
Table 4: Summary of lipid laboratory values at baseline (screening) and week 48 - study
Enfuvirtid og Viramune kan coadministreres uden dosisjustering.
Enfuvirtide and Viramune can be coadministered without dose adjustments.
Ikke almindelig (kan forekomme hos op til 1 ud af 100 patienter): - allergiske reaktioner (overfølsomhed) - allergisk reaktion karakteriseret ved udslæt, hævelse af ansigt, åndenød (bronkospasme) eller anafylaktisk shock - lægemiddelforårsaget udslæt (med eosinofili og systemiske symptomer) - pludselig og kraftig leverbetændelse (fulminant leverbetændelse) - alvorlige og livstruende hudreaktioner (Stevens-Johnsons syndrom/toksisk epidermal nekrolyse) - nedsat antal af røde blodlegemer (anæmi) - nedsat antal af hvide blodlegemer (granulocytopeni) - gulsot - nældefeber - væskedannelse under huden (angioødem) - muskelsmerter (myalgi) - ledsmerter - nedsat indhold af fosfat i blodet - forhøjet blodtryk
Uncommon (may affect up to 1 in 100 people): - allergic reactions (hypersensitivity) - allergic reaction characterized by rash, swelling of the face, difficulty breathing (bronchial spasm) or anaphylactic shock - drug reaction with systemic symptoms (drug reaction with eosinophilia and systemic symptoms) - sudden and intense inflammation of the liver (fulminant hepatitis) - severe and life-threatening skin rashes (Stevens Johnson Syndrome/toxic epidermal necrolysis) - decreased numbers of red blood cells (anaemia) - decreased numbers of white blood cells (granulocytopenia) - yellow skin (jaundice) - hives (urticaria) - fluid under the skin (angioneurotic oedema) - muscle pain (myalgia) - joint pain (arthralgia) - decreased blood phosphorus - increased blood pressure
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER 1 depottablet indeholder 100 mg nevirapin (vandfri).
STATEMENT OF ACTIVE SUBSTANCE(S) Each prolonged-release tablet contains 100 mg of nevirapine (as anhydrous)
0,58-0,83 200 (2 x 100 mg) 0,84-1,16 300 (3 x 100 mg)
Recommended paediatric dosing by BSA after the lead-in period BSA (m2) Viramune prolonged-release tablets dose (mg) 0.58-0.83 200 (2 x 100 mg) 0.84-1.16 300 (3 x 100 mg) 400 (1 x 400 mg)
LÆGEMIDLETS NAVN Viramune 100 mg depottabletter nevirapin
NAME OF THE MEDICINAL PRODUCT Viramune 100 mg prolonged-release tablets nevirapine
Dette antyder, at patienter med forværring af den hepatiske funktion og ascites risikerer akkumulering af nevirapin i den systemiske cirkulation.
n=4), a significant increase in the AUC of nevirapine was observed in one Child-Pugh B patient with ascites suggesting that patients with worsening hepatic function and ascites may be at risk of accumulating nevirapine in the systemic circulation.
Viramune depottabletter er ikke blevet undersøgt hos patienter med nedsat leverfunktion og Viramune tabletter bør benyttes.
Viramune prolonged-release tablets have not been studied in patients with renal dysfunction and Viramune immediate-release should be used.
Ved alle patientbesøg frem til sidste patient fuldførte uge 144 blev der foretaget bivirkningsregistrering.
The safety data include all patient visits up to the time of the last patient's completion of study week 144.
Ikke almindelig (kan forekomme hos op til 1 ud af 100 patienter): - allergiske reaktioner (overfølsomhed) - allergisk reaktion karakteriseret ved udslæt, hævelse af ansigt, åndenød (bronkiespasmer) eller anafylaktisk shock - lægemiddelforårsaget udslæt (med eosinofili og systemiske symptomer) - pludselig og kraftig leverbetændelse (fulminant leverbetændelse) - alvorlige og livstruende hudreaktioner (Stevens-Johnsons syndrom/toksisk epidermal nekrolyse) - gulsot - nældefeber - væskedannelse under huden (angioødem) - opkastning - muskelsmerter (myalgi) - ledsmerter - nedsat antal af hvide blodlegemer (granulocytopeni) - leverfunktionsprøver uden for normalområdet - nedsat indhold af fosfat i blodet - forhøjet blodtryk
Uncommon (may affect up to 1 in 100 people): - allergic reactions (hypersensitivity) - allergic reaction characterized by rash, swelling of the face, difficulty breathing (bronchial spasm) or anaphylactic shock - drug reaction with systemic symptoms (drug reaction with eosinophilia and systemic symptoms) - sudden and intense inflammation of the liver (fulminant hepatitis) - severe and life-threatening skin rashes (Stevens Johnson Syndrome/toxic epidermal necrolysis) - yellow skin (jaundice) - hives (urticaria) - fluid under the skin (angioneurotic oedema) - vomiting - muscle pain (myalgia) - joint pain (arthralgia) - decreased numbers of white blood cells (granulocytopenia) - abnormal liver function tests - decreased blood phosphorus - increased blood pressure
Entecavir og Viramune kan coadministreres uden dosisjustering.
Entecavir and Viramune may be coadministered without dose adjustments.
Overvejelser i forbindelse med fastsættelse af dosis Dosis af Viramune bør ikke øges til patienter, som udvikler udslæt i optrapningsperioden på 14 dage med 200 mg/dag, før udslættet er forsvundet.
Patients experiencing rash during the 14-day lead-in period of 200 mg/day should not have their Viramune dose increased until the rash has resolved.
Hvis du nogensinde får udslæt i mild grad uden nogle af de andre bivirkninger, skal du straks informere lægen om det.
If you ever have only mild rash symptoms without any other reaction please inform your doctor immediately, who will advise you whether you should stop taking Viramune.
Risikofaktorer for udvikling af denne sygdom er blandt mange: Længden af den tidsperiode, hvor du er blevet behandlet med flere antiretrovirale lægemidler, anvendelse af kortikosteroider, alkoholforbrug, alvorligt nedsat immunforsvar, samt højt BMI (body-mass-index) Stivhed, ømhed og smerter i ledene (især hofte, knæ og skulder) samt besvær med at bevæge sig, er tegn på knoglenekrose.
The length of combination antiretroviral therapy, corticosteroid use, alcohol consumption, severe weakness of the immune system and higher body mass index may be some of the many risk factors for developing this disease.
Doseringsregimenet for lead-in af Viramune 200 mg én gang dagligt bør ikke administreres i mere end 28 dage, da der er risiko for undereksponering og resistens.
The 200 mg once daily dosing regimen of Viramune immediate-release should not be continued beyond 28 days at which point in time an alternative treatment should be sought due to the possible risk of underexposure and resistance.
3, mænd med over 400 celler/mm
3 or in adult males with CD4 cell counts greater than 400 cells/mm
Tag ikke Viramune hvis du er blevet udsat for hiv, med med mindre du er blevet diagnosticeret med hiv, og lægen har foreskrevet det. Viramune kan ikke helbrede en hiv-infektion.
If you are taking nevirapine and zidovudine concomitantly please inform your doctor since he might need to check your white blood cells.Do not take Viramune after an exposure to HIV unless you have been diagnosed with HIV and instructed to do so by your doctor.
Hvis dit barn får nogen form for udslæt i denne periode, må behandling med Viramune depottabletter ikke opstartes.
If your child develops any rash during this period, do not start taking Viramune prolonged-release tablets but consult your child's doctor.
200 mg som dagsdosis bør ikke administreres i mere end 28 dage, da der er risiko for undereksponering og resistens og en alternativ medicinsk behandling bør vælges.
The 200 mg once daily dosing regimen should not be continued beyond 28 days at which point in time an alternative treatment should be sought due to the possible risk of underexposure and resistance.
LÆGEMIDLETS NAVN Viramune 400 mg depottabletter
NAME OF THE MEDICINAL PRODUCT Viramune 400 mg prolonged-release tablets
anafylaktisk reaktion, angioødem, urticaria)
anaphylactic reaction, angioedema and urticaria) has been reported.
Adefovir og Viramune kan coadministreres uden dosisjustering.
Adefovir and Viramune may be coadministered without dose adjustments.
Viramune-behandlingen.
Viramune.
Stavudin og Viramune kan coadministreres uden dosisjustering.
Stavudine and Viramune can be coadministered without dose adjustments.
Dosis i optrapningsperioden ( de første 14 dage) med Viramune 200 mg tabletter eller Viramune 50 mg/5ml oral suspension:
Lead-in dosing with Viramune 200 mg tablets or Viramune 50 mg/5 ml oral suspension (first 14 days): All paediatric patients should initiate therapy with 150 mg/m2 (calculated using the Mosteller formula)
Hepatitis (inklusive svær og livstruende hepatotoksicitet) (1,9 %)
Gastrointestinal disorders Common nausea, vomiting, abdominal pain, diarrhoea Hepatobiliary disorders Common hepatitis (including severe and life-threatening hepatotoxicity) (1.9%) Uncommon jaundice
MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/97/055/006
MARKETING AUTHORISATION NUMBER(S) EU/1/97/055/006
Før behandlingen med nevirapin igangsættes samt med passende mellemrum undervejs i behandlingen, skal der udføres biokemiske tests herunder test af leverfunktionen.
Clinical chemistry tests, which include liver function tests, should be performed prior to initiating nevirapine therapy and at appropriate intervals during therapy.
MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/97/055/002
MARKETING AUTHORISATION NUMBER(S) EU/1/97/055/002
Viramune er indiceret til behandling af hiv-1 smittede patienter (voksne, unge og børn) i kombination med andre antivirale lægemidler (se pkt.
Viramune is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adults, adolescents, and children of any age (see section 4.2).
Ribaverin og Viramune kan coadministreres uden dosisjustering.
Ribavirin and Viramune may be coadministered without dose adjustments.
Interferoner og Viramune kan coadministreres uden dosisjustering.
Interferons and Viramune may be coadministered without dose adjustments.
3 for de, der fik Viramune 200 mg, og de, der fik Viramune i depotform.
3 for the groups receiving Viramune immediate-release and Viramune prolonged-release respectively.
Stevens-Johnsons syndrom/toksisk epidermal nekrolyse (som kan være letal) (0,6 %), angioødem, urticaria Knogler, led, muskler og bindevæv Ikke almindelig :
Uncommon Stevens-Johnson Syndrome/toxic epidermal necrolysis (which may be fatal) (0.6 %), angioedema, urticaria
Hos 1,1 % af patienterne i optrapningsfasen med Viramune 200 mg opstod der svært eller livstruende udslæt, der blev betragtet som nevirapinrelateret.
Severe or lifethreatening rash considered related to nevirapine treatment occurred in 1.1 % of patients during the lead-in phase with Viramune immediate-release.
DMPA og Viramune kan coadministreres uden dosisjustering.
DMPA and Viramune can be co-administered without dose adjustments.
MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/97/055/004
MARKETING AUTHORISATION NUMBER(S) EU/1/97/055/004
Darunavir og Viramune kan coadministreres uden dosisjustering.
Darunavir and Viramune can be coadministered without dose adjustments.
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE TEKST PÅ ÆSKE TIL BEHOLDER
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
LÆGEMIDLETS NAVN Viramune 100 mg depottabletter
NAME OF THE MEDICINAL PRODUCT Viramune 100 mg prolonged-release tablets
MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/97/055/007
MARKETING AUTHORISATION NUMBER(S) EU/1/97/055/007
Entecavir er ikke substrat, induktor eller hæmmer af CYP-enzymer.
Entecavir is not a substrate, inducer or an inhibitor of cytochrome P450 (CYP450) enzymes.
Lægen vil råde dig med hensyn til, om du skal stoppe Viramune-behandlingen.
Depending on the outcome your doctor may decide to interrupt or stop Viramune treatment.
Fosamprenavir/ritonav ir 700/100 mg 2 gange daglig
Fosamprenavir/ritona vir 700/100 mg BID
Køn
PIs
NNRTI'er Efavirenz 600 mg 4 gange dagligt
NNRTIs Efavirenz 600 mg QD
- unge under 16 år, som - vejer 50 kg eller mere - eller har et legemsoverfladeareal på over 1,25 m
Viramune 400 mg prolonged-release tablets can be taken by children if they: - are  8 years of age and weigh 43.8 kg or more - are older than 3 years of age and below 8 years of age and weigh 25 kg or more - have a body surface area of 1.17 square metres or above.
tilfælde af Stevens-Johnsons syndrom (SJS) og toksisk epidermal nekrolyse (TEN)) eller alvorlig hepatitis/leversvigt.
Uncommon Stevens-Johnson syndrome/ toxic epidermal necrolysis (which may be fatal)
Dosis 7 mg/kg
300 mg QD
En tablet indeholder mindre end 1 mmol (23 mg) natrium, dvs. den er i det væsentlige natrium-fri. Alle hjælpestoffer er anført under pkt.
Each tablet contains less than 1 mmol sodium (23 mg), that is to say essentially ‘sodium-free'.
Hvis du har taget for meget Viramune
If you take more Viramune than you should
Den 24. juli 2014 EMA/444346/2014
24 July 2014 EMA/444346/2014
Tlf. +44 (0)20 7418 8427 E-mail: 19TUpress@ema.europa.euU1
Tel. +44 (0)20 7418 8427 E-mail: press@ema.europa.eu
• Patienter, der har spørgsmål eller betænkeligheder, bør kontakte lægen eller en anden sundhedsperson.
• Patients who have questions or concerns should consult their doctor or another healthcare professional.
Gennemgangen blev foretaget af Udvalget for Risikovurdering inden for Lægemiddelvurdering (PRAC).
The review was first conducted by the Pharmacovigilance Risk Assessment Committee (PRAC).
Gennemgangen af orale metadonlægemidler indeholdende povidon blev indledt den 10. april 2014 i henhold til artikel 107i i direktiv 2001/83/EF (også kaldet EU-hasteproceduren).
The review of oral methadone medicines containing povidone was initiated on 10 April 2014 under Article 107i of Directive 2001/83/EC, also known as the ‘urgent Union procedure'.
Virkningen af metadon til opioidsubstitutionsbehandling blev anerkendt og er ikke draget i tvivl ved denne gennemgang.
The efficacy of methadone in opioid substitution therapy was acknowledged and was not questioned in this review.
Metadon anvendes desuden til behandling af svære smerter.
Methadone is also used in the treatment of severe pain.
Orale tabletter er godkendt i Danmark, Finland, Ungarn, Island, Norge, Rumænien, Spanien og Sverige.
Oral solutions have been authorised in Denmark, Finland, Malta, Norway, Sweden and the United Kingdom; oral tablets have been authorised in Denmark, Finland, Hungary, Iceland, Norway, Romania, Spain and Sweden.
Metadonbehandling bør anvendes i forbindelse med et bredere rehabiliteringsforløb.
Treatment with methadone should be given in the context of a wider rehabilitation program.
Disse lægemidler vil være suspenderet, indtil de er blevet omformuleret.
These products will remain suspended until they have been reformulated.
Lægemidler indeholdende povidon er godkendt ved nationale procedurer i en række europæiske lande.
Methadone medicines containing povidone have been authorised via national procedures in several European countries.
Disse lægemidler vil derfor fortsat være på markedet, men der vil blive
Therefore, these products will remain on the
• Mens disse lægemidler er suspenderet, bør sundhedspersoner lade patienterne overgå til andre metadonlægemidler.
• While these medicines are suspended, healthcare professionals should switch their patients to alternative methadone products.